339P Analysis of first- and second-line immunotherapy efficacy in metastatic non-small cell lung cancer with low PD-L1 expression

C Mckay,J Cheng,P.Y Yip,A Tognela,V.J Bray,P.S Kok

doi:10.1016/j.annonc.2022.10.377

339P Analysis of first- and second-line immunotherapy efficacy in metastatic non-small cell lung cancer with low PD-L1 expression

C Mckay, J Cheng + Show 4 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.377

Copy DOI

Journal: Annals of Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Western Sydney University

#Second-line Immune Checkpoint Inhibitors #Outcomes Of Advanced Non-small Cell Lung Cancer Patients + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Immune checkpoint inhibitors (ICI) improve overall survival (OS) in non-small cell lung cancer (NSCLC) but the efficacy of first- vs second-line ICI is unknown. We compared the outcomes of advanced NSCLC patients with <50% PD-L1 expression who received first- and second-line ICI.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.